Ryne Biotechnology

Based in California, US, Ryne Biotechnology Inc. operates as a biotechnology company specializing in neuron replacement therapies. In February 2023 the firm raised USD 4 million in grant funding from investor California Institute for Regenerative Medicine. The company is working on the development of neuron replacement therapies as potential disease-modifying treatments for neurological disorders, by leveraging induced pluripotent stem cell (iPSC) technology.

The company’s lead program is iPSC dopamine neuron progenitor (RNDP-001) for the treatment of inherited and idiopathic forms of Parkinson’s Disease. Other programs in Ryne’s pipeline are Gene-modified iPSC including RNDP-002 for mild to severe rapid progressing Parkinson’s disease, and RNDP-003 for young onset Parkinson’s disease, in discovery and pre-clinical stages as of February 2023. The company plans to utilize its February 2023 funding to accelerate its lead program RNDP-001, through the submission of an Investigational New Drug (IND) application.